Freshfields Bruckhaus Deringer (‘Freshfields’) has advised Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (‘Mindray’) on its acquisition of 100 per cent of the issued and outstanding shares of Finland-based Hytest Invest Oy (‘Hytest’) and its subsidiaries via Mindray’s indirect subsidiary, Mindray Medical Netherlands B.V.. The value of the transaction was €545m.
The target business was sold by way of a highly competitive auction by a PE seller on an extremely short timetable. Quick execution, minimal regulatory conditions and the availability of unconditional offshore funding were critical to the success of Mindray’s bid.
Mindray is a leading global provider of medical devices and solutions. The company employs advanced technologies and adapts them to clinical scenarios by applying its global R&D, marketing and service network. Hytest develops and supplies immunological reagents for the in vitro diagnostic and research community.
The Freshfields team advising on the transaction was led by partner Richard Perks, supported closely by partners Alan Wang and Alastair Mordaunt. Network assistance was provided by Thijs Flokstra, Anna Nersesian, Igor Gerber, Aimen Mir, Frank Rohling, and Bruce McCulloch. The transactional partners were supported by counsel Ya Ma. The antitrust partners were supported by counsel Alexander Viktorov and Aude Guyon. Employment law advice was provided by counsel Olga Chislova.
